MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million

Reuters2026/08/13 11:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MediWound posted Q2 revenue of USD 3.1 million, down 45.85% year over year; operating loss widened to USD 9.5 million.
Net loss narrowed to USD 7.4 million, or USD 0.57 per share, versus USD 13.3 million, on non-cash financial income.
RD expense rose to USD 5.9 million from USD 3.5 million, reflecting higher investment in the EscharEx Phase III VALUE trial.
Cash, cash equivalents and deposits totaled USD 36 million at June 30, down from USD 54 million at year-end 2025.
Full-year 2026 revenue guidance of USD 24-26 million was reaffirmed, with MSA revenue under Vericel’s BARDA contract expected in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9808849) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million

You may also like

Crypto prices